Portfolio Holdings Detail for ISIN IE00BMBKBZ46
Stock Name / Fund iShares S&P 500 Health Care Sector UCITS ETF
Issuer Blackrock
Entity holding fund iShares V Public Limited Company
Entity Type
Entity LEI 549300QETNU1W5JY7Z94
ETF Ticker IUHE.AS(EUR) CXE
ETF Ticker IUHE(EUR) Euronext Amsterdam

Holdings detail for REGN

Stock Name	Regeneron Pharmaceuticals Inc
Ticker	REGN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US75886F1075
LEI	549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria: (RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages: Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis: Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00: Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL: Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors: Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says: Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN: In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC: Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.: Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00: Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.: D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares S&P 500 Health Care Sector UCITS ETF REGN holdings

Date	Number of REGN Shares Held	Base Market Value of REGN Shares	Local Market Value of REGN Shares	Change in REGN Shares Held	Change in REGN Base Value	Current Price per REGN Share Held	Previous Price per REGN Share Held
2025-09-26 (Friday)	48,267	USD 27,217,761	USD 27,217,761
2025-09-25 (Thursday)	48,267	USD 26,812,801	USD 26,812,801	0	USD -1,036,293	USD 555.51	USD 576.98
2025-09-24 (Wednesday)	48,267	USD 27,849,094	USD 27,849,094
2025-09-18 (Thursday)	48,983	USD 29,326,612	USD 29,326,612	57	USD 680,439	USD 598.71	USD 585.5
2025-09-17 (Wednesday)	48,926	USD 28,646,173	USD 28,646,173	0	USD 510,787	USD 585.5	USD 575.06
2025-09-16 (Tuesday)	48,926	USD 28,135,386	USD 28,135,386	0	USD 120,848	USD 575.06	USD 572.59
2025-09-15 (Monday)	48,926	USD 28,014,538	USD 28,014,538	0	USD 615,978	USD 572.59	USD 560
2025-09-12 (Friday)	48,926	USD 27,398,560	USD 27,398,560	151	USD -315,395	USD 560	USD 568.2
2025-09-11 (Thursday)	48,775	USD 27,713,955	USD 27,713,955	57	USD 635,029	USD 568.2	USD 555.83
2025-09-10 (Wednesday)	48,718	USD 27,078,926	USD 27,078,926	57	USD -2,380	USD 555.83	USD 556.53

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE00BMBKBZ46

Show aggregate share trades of REGN

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-09-18 BUY 57 598.710* 640.19
2025-09-12 BUY 151 560.000* 641.70
2025-09-11 BUY 57 568.200* 642.11
2025-09-10 BUY 57 555.830* 642.60
2025-08-20 BUY 114 591.010* 643.66
2025-08-19 BUY 57 571.780* 644.07
2025-08-18 BUY 285 573.910* 644.48
2025-08-15 BUY 849 580.410* 644.86
2025-08-14 BUY 342 565.970* 645.33
2025-08-13 BUY 228 561.550* 645.83
2025-07-30 BUY 58 554.580* 646.91
2025-07-17 SELL -58 550.000* 652.05 Profit of 37,819 on sale
2025-07-15 SELL -232 547.960* 653.39 Profit of 151,587 on sale
2025-07-14 SELL -580 570.590* 653.93 Profit of 379,280 on sale
2025-07-09 SELL -58 552.580* 655.80 Profit of 38,036 on sale
2025-07-07 SELL -116 538.110* 657.31 Profit of 76,248 on sale
2025-07-02 BUY 58 547.740* 659.57
2025-06-24 SELL -986 522.270* 664.45 Profit of 655,147 on sale
2025-06-23 BUY 58 511.920* 665.54
2025-06-20 SELL -491 509.720* 666.66 Profit of 327,330 on sale
2025-06-18 SELL -58 513.580* 668.89 Profit of 38,796 on sale
2025-06-17 BUY 696 508.860* 670.07
2025-06-13 SELL -116 529.240* 672.22 Profit of 77,978 on sale
2025-06-11 SELL -58 518.600* 674.53 Profit of 39,122 on sale
2025-06-10 SELL -116 523.530* 675.68 Profit of 78,379 on sale
2025-06-09 SELL -174 517.600* 676.89 Profit of 117,780 on sale
2025-05-21 SELL -57 604.620* 691.35 Profit of 39,407 on sale
2025-05-20 SELL -114 614.790* 692.01 Profit of 78,889 on sale
2025-05-15 SELL -171 584.990* 694.66 Profit of 118,787 on sale
2025-05-14 SELL -171 571.360* 695.76 Profit of 118,975 on sale
2025-05-13 BUY 57 574.160* 696.86
2025-05-09 SELL -57 527.780* 699.52 Profit of 39,873 on sale
2025-05-08 BUY 114 547.670* 700.93
2025-05-01 BUY 114 590.000* 706.62
2025-04-24 SELL -57 599.760* 712.25 Profit of 40,598 on sale
2025-04-23 BUY 171 587.850* 713.53
2025-04-15 SELL -57 557.910* 723.43 Profit of 41,236 on sale
2025-04-10 SELL -114 546.390* 729.10 Profit of 83,117 on sale
2025-04-08 SELL -57 556.810* 732.87 Profit of 41,774 on sale
2025-04-07 SELL -57 572.780* 734.76 Profit of 41,881 on sale
2025-04-04 SELL -114 573.450* 736.68 Profit of 83,981 on sale
2025-04-02 BUY 57 625.600* 738.02
2025-04-01 BUY 513 617.000* 739.49
2025-03-31 SELL -342 634.230* 740.79 Profit of 253,350 on sale
2025-03-28 BUY 57 637.360* 742.08
2025-03-26 SELL -36 640.140* 744.75 Profit of 26,811 on sale
2025-03-21 BUY 696 658.480* 748.49
2025-03-20 BUY 228 662.620* 749.65
2025-03-17 SELL -57 678.420* 752.94 Profit of 42,918 on sale
2025-03-12 SELL -42 689.500* 756.20 Profit of 31,760 on sale
2025-03-07 BUY 57 707.510* 757.71
2025-02-28 SELL -171 698.740* 762.38 Profit of 130,366 on sale
2025-02-25 BUY 570 723.470* 765.03
2025-02-20 BUY 399 696.020* 768.40
2025-02-19 BUY 171 685.660* 769.94
2025-02-18 BUY 114 680.000* 771.63
2025-02-13 BUY 285 674.270* 777.50
2025-02-04 BUY 228 697.050* 790.92
2025-01-31 BUY 57 672.980* 796.82
2025-01-29 BUY 57 687.270* 802.55
2025-01-27 BUY 114 684.710* 808.87
2025-01-24 BUY 57 675.790* 812.57
2025-01-02 SELL -2,323 715.190* 818.90 Profit of 1,902,312 on sale
2024-12-10 SELL -57 778.500* 820.13 Profit of 46,747 on sale
2024-12-09 SELL -1,482 788.000* 821.13 Profit of 1,216,917 on sale
2024-12-03 SELL -684 749.570* 829.52 Profit of 567,389 on sale
2024-12-02 SELL -285 762.340* 832.00 Profit of 237,121 on sale
2024-11-29 SELL -57 750.220* 835.15 Profit of 47,604 on sale
2024-11-22 SELL -570 738.000* 855.41 Profit of 487,584 on sale
2024-11-21 SELL -285 744.500* 860.96 Profit of 245,373 on sale
2024-11-20 BUY 456 743.350* 867.15
2024-11-18 SELL -684 762.000* 880.54 Profit of 602,289 on sale
2024-11-11 BUY 513 825.680* 888.17
2024-11-08 SELL -1,824 828.420* 892.43 Profit of 1,627,800 on sale
2024-11-07 SELL -114 824.480* 897.66 Profit of 102,333 on sale
2024-11-01 SELL -114 843.600* 927.90 Profit of 105,780 on sale
2024-10-31 SELL -228 838.200* 939.11 Profit of 214,117 on sale
2024-10-30 BUY 57 922.790* 941.44
2024-10-29 BUY 342 927.330* 943.79
2024-10-28 SELL -171 928.610* 946.83 Profit of 161,908 on sale
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-09-18	BUY	57	598.710*	640.19
2025-09-12	BUY	151	560.000*	641.70
2025-09-11	BUY	57	568.200*	642.11
2025-09-10	BUY	57	555.830*	642.60
2025-08-20	BUY	114	591.010*	643.66
2025-08-19	BUY	57	571.780*	644.07
2025-08-18	BUY	285	573.910*	644.48
2025-08-15	BUY	849	580.410*	644.86
2025-08-14	BUY	342	565.970*	645.33
2025-08-13	BUY	228	561.550*	645.83
2025-07-30	BUY	58	554.580*	646.91
2025-07-17	SELL	-58	550.000*	652.05 Profit of 37,819 on sale
2025-07-15	SELL	-232	547.960*	653.39 Profit of 151,587 on sale
2025-07-14	SELL	-580	570.590*	653.93 Profit of 379,280 on sale
2025-07-09	SELL	-58	552.580*	655.80 Profit of 38,036 on sale
2025-07-07	SELL	-116	538.110*	657.31 Profit of 76,248 on sale
2025-07-02	BUY	58	547.740*	659.57
2025-06-24	SELL	-986	522.270*	664.45 Profit of 655,147 on sale
2025-06-23	BUY	58	511.920*	665.54
2025-06-20	SELL	-491	509.720*	666.66 Profit of 327,330 on sale
2025-06-18	SELL	-58	513.580*	668.89 Profit of 38,796 on sale
2025-06-17	BUY	696	508.860*	670.07
2025-06-13	SELL	-116	529.240*	672.22 Profit of 77,978 on sale
2025-06-11	SELL	-58	518.600*	674.53 Profit of 39,122 on sale
2025-06-10	SELL	-116	523.530*	675.68 Profit of 78,379 on sale
2025-06-09	SELL	-174	517.600*	676.89 Profit of 117,780 on sale
2025-05-21	SELL	-57	604.620*	691.35 Profit of 39,407 on sale
2025-05-20	SELL	-114	614.790*	692.01 Profit of 78,889 on sale
2025-05-15	SELL	-171	584.990*	694.66 Profit of 118,787 on sale
2025-05-14	SELL	-171	571.360*	695.76 Profit of 118,975 on sale
2025-05-13	BUY	57	574.160*	696.86
2025-05-09	SELL	-57	527.780*	699.52 Profit of 39,873 on sale
2025-05-08	BUY	114	547.670*	700.93
2025-05-01	BUY	114	590.000*	706.62
2025-04-24	SELL	-57	599.760*	712.25 Profit of 40,598 on sale
2025-04-23	BUY	171	587.850*	713.53
2025-04-15	SELL	-57	557.910*	723.43 Profit of 41,236 on sale
2025-04-10	SELL	-114	546.390*	729.10 Profit of 83,117 on sale
2025-04-08	SELL	-57	556.810*	732.87 Profit of 41,774 on sale
2025-04-07	SELL	-57	572.780*	734.76 Profit of 41,881 on sale
2025-04-04	SELL	-114	573.450*	736.68 Profit of 83,981 on sale
2025-04-02	BUY	57	625.600*	738.02
2025-04-01	BUY	513	617.000*	739.49
2025-03-31	SELL	-342	634.230*	740.79 Profit of 253,350 on sale
2025-03-28	BUY	57	637.360*	742.08
2025-03-26	SELL	-36	640.140*	744.75 Profit of 26,811 on sale
2025-03-21	BUY	696	658.480*	748.49
2025-03-20	BUY	228	662.620*	749.65
2025-03-17	SELL	-57	678.420*	752.94 Profit of 42,918 on sale
2025-03-12	SELL	-42	689.500*	756.20 Profit of 31,760 on sale
2025-03-07	BUY	57	707.510*	757.71
2025-02-28	SELL	-171	698.740*	762.38 Profit of 130,366 on sale
2025-02-25	BUY	570	723.470*	765.03
2025-02-20	BUY	399	696.020*	768.40
2025-02-19	BUY	171	685.660*	769.94
2025-02-18	BUY	114	680.000*	771.63
2025-02-13	BUY	285	674.270*	777.50
2025-02-04	BUY	228	697.050*	790.92
2025-01-31	BUY	57	672.980*	796.82
2025-01-29	BUY	57	687.270*	802.55
2025-01-27	BUY	114	684.710*	808.87
2025-01-24	BUY	57	675.790*	812.57
2025-01-02	SELL	-2,323	715.190*	818.90 Profit of 1,902,312 on sale
2024-12-10	SELL	-57	778.500*	820.13 Profit of 46,747 on sale
2024-12-09	SELL	-1,482	788.000*	821.13 Profit of 1,216,917 on sale
2024-12-03	SELL	-684	749.570*	829.52 Profit of 567,389 on sale
2024-12-02	SELL	-285	762.340*	832.00 Profit of 237,121 on sale
2024-11-29	SELL	-57	750.220*	835.15 Profit of 47,604 on sale
2024-11-22	SELL	-570	738.000*	855.41 Profit of 487,584 on sale
2024-11-21	SELL	-285	744.500*	860.96 Profit of 245,373 on sale
2024-11-20	BUY	456	743.350*	867.15
2024-11-18	SELL	-684	762.000*	880.54 Profit of 602,289 on sale
2024-11-11	BUY	513	825.680*	888.17
2024-11-08	SELL	-1,824	828.420*	892.43 Profit of 1,627,800 on sale
2024-11-07	SELL	-114	824.480*	897.66 Profit of 102,333 on sale
2024-11-01	SELL	-114	843.600*	927.90 Profit of 105,780 on sale
2024-10-31	SELL	-228	838.200*	939.11 Profit of 214,117 on sale
2024-10-30	BUY	57	922.790*	941.44
2024-10-29	BUY	342	927.330*	943.79
2024-10-28	SELL	-171	928.610*	946.83 Profit of 161,908 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	208,659	1,635	312,812	66.7%
2025-09-18	236,485	3,679	387,519	61.0%
2025-09-17	229,191	716	370,895	61.8%
2025-09-16	173,632	584	271,020	64.1%
2025-09-15	204,491	251	334,496	61.1%
2025-09-12	117,504	33	222,760	52.7%
2025-09-11	125,478	3,137	286,516	43.8%
2025-09-10	195,068	481	339,885	57.4%
2025-09-09	129,168	994	274,520	47.1%
2025-09-08	250,895	396	527,062	47.6%
2025-09-05	170,149	290	289,566	58.8%
2025-09-04	188,227	2,103	360,619	52.2%
2025-09-03	185,679	344	438,111	42.4%
2025-09-02	191,954	138	476,288	40.3%
2025-08-29	133,226	685	236,726	56.3%
2025-08-28	116,560	2,177	256,675	45.4%
2025-08-27	113,719	465	243,836	46.6%
2025-08-26	210,376	450	400,199	52.6%
2025-08-25	149,130	68	363,377	41.0%
2025-08-22	211,822	3,244	701,770	30.2%
2025-08-21	257,492	3,416	446,439	57.7%
2025-08-20	327,738	572	559,133	58.6%
2025-08-19	118,472	2,191	324,311	36.5%
2025-08-18	146,282	388	277,909	52.6%
2025-08-15	209,923	3,375	441,752	47.5%
2025-08-14	157,569	3,623	429,327	36.7%
2025-08-13	111,342	233	362,786	30.7%
2025-08-12	117,647	171	310,775	37.9%
2025-08-11	129,513	2,676	284,757	45.5%
2025-08-08	128,559	1,038	431,841	29.8%
2025-08-07	166,648	1,560	352,877	47.2%
2025-08-06	176,311	624	397,089	44.4%
2025-08-05	154,257	115	353,744	43.6%
2025-08-04	200,758	1,913	409,897	49.0%
2025-08-01	349,775	3,745	728,720	48.0%
2025-07-31	222,350	476	549,344	40.5%
2025-07-30	106,839	1,689	231,761	46.1%
2025-07-29	149,359	276	292,667	51.0%
2025-07-28	103,687	1,380	245,287	42.3%
2025-07-25	103,783	556	259,069	40.1%
2025-07-24	156,974	2,397	291,677	53.8%
2025-07-23	168,734	1,708	355,372	47.5%
2025-07-22	116,324	617	304,880	38.2%
2025-07-21	98,482	900	250,107	39.4%
2025-07-18	183,174	1,051	391,909	46.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares S&P 500 Health Care Sector UCITS ETF
Issuer	Blackrock
Entity holding fund	iShares V Public Limited Company
Entity Type
Entity LEI	549300QETNU1W5JY7Z94
ETF Ticker	IUHE.AS(EUR) CXE
ETF Ticker	IUHE(EUR) Euronext Amsterdam